The pharmacokinetics among children has been altered dynamically. The difference between children and adults is caused by immaturity in things such as metabolic enzymes and transport proteins. The periods when these alterations happen vary from a few days to some years after birth. We hypothesized that the effect of gene polymorphisms associated with the dose of medicine could be influenced by age. In this study, we analyzed 51 patients with childhood acute lymphoblastic leukemia (ALL) retrospectively. We examined the associations between the polymorphism in NUDT15 and clinical data, especially the dose of 6-mercaptopurine (6-MP). Ten of the patients were heterozygous for the variant allele in NUDT15. In patients under 7 years old with NUDT15 variant allele, the average administered dose of 6-MP was lower than that for the patients homozygous for the wild-type allele (P=0.04). Genotyping of NUDT15 could be a beneficial to estimate the tolerated dose of 6-MP for patients with childhood ALL, especially at a preschool age in Japan. Furthermore, the analysis with stratification by age might be useful in pharmacogenomics among children.

Download full-text PDF

Source
http://dx.doi.org/10.1038/jhg.2016.55DOI Listing

Publication Analysis

Top Keywords

genotyping nudt15
8
acute lymphoblastic
8
lymphoblastic leukemia
8
preschool age
8
patients childhood
8
variant allele
8
dose 6-mp
8
dose
5
patients
5
nudt15 predict
4

Similar Publications

Efficacy and safety of azathioprine in patients with Cronkhite-Canada syndrome: a case series from Peking Union Medical College Hospital.

BMC Pharmacol Toxicol

December 2024

Department of Gastroenterology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China.

Background: Cronkhite-Canada syndrome (CCS) is a rare non-hereditary chronic inflammatory disease characteristic of gastrointestinal polyps and ectodermal abnormalities. Corticosteroid therapy is the mainstay medication for CCS. Few studies indicated immunosuppressants might be the choices for patients with steroid refractory, steroid dependent or intolerant.

View Article and Find Full Text PDF

Pharmacogenomic profiling of the South Korean population: Insights and implications for personalized medicine.

Front Pharmacol

December 2024

Seoul National University Biomedical Informatics (SNUBI), Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.

Adverse drug reactions (ADRs) pose substantial public health issues, necessitating population-specific characterization due to variations in pharmacogenes. This study delineates the pharmacogenomic (PGx) landscape of the South Korean (SKR) population, focusing on 21 core pharmacogenes. Whole genome sequencing (WGS) was conducted on 396 individuals, including 99 healthy volunteers, 95 patients with chronic diseases, 81 with colon cancer, 81 with breast cancer, and 40 with gastric cancer, to identify genotype-specific drug dosing recommendations.

View Article and Find Full Text PDF

Nudix hydrolase 15 (NUDT15) deficiency is strongly associated with thiopurine-induced myelosuppression. Currently, testing for NUDT15 deficiency is based on the genotyping of the most frequent and clinically characterized no-function variants, that is, *2, *3 and *9. The Hispanic/Latino-predominant variant NUDT15 *4 (p.

View Article and Find Full Text PDF
Article Synopsis
  • Thiopurine drugs are crucial for managing inflammatory bowel disease (IBD), but they can cause side effects, particularly thiopurine-induced myelosuppression (TIM).
  • A study in the Netherlands explored the frequency of the NUDT15*3 genetic polymorphism and its connection to TIM in IBD patients.
  • Out of 988 patients, 1.3% had the NUDT15*3 variant; among those on thiopurines, 50% of carriers developed TIM compared to just 2.3% of non-carriers, indicating the importance of genetic testing before treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Azathioprine (AZA), commonly used for autoimmune disorders and organ transplants, shows potential for modern applications in viral, rheumatic, and skin diseases.
  • Advances in pharmacogenomics and nanotechnology may enhance AZA's effectiveness while reducing side effects, particularly by utilizing the active metabolites 6-mercaptopurine and 6-thioguanine.
  • The study suggests that personalized medicine approaches, including genetic testing and innovative drug delivery systems, can improve treatment outcomes for conditions like systemic lupus erythematosus and psoriasis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!